retatrutide and test 10mg — Triple Agonist GLP-1/GIP/Glucagon Research Peptide Retatrutide 10mg Triple Agonist |

Improved blood sugar balance and metabolic control

Additionally, GLP-1 RAs have shown potential in mitigating inflammation in diabetic kidney disease by inhibiting angiotensin II signaling, downregulating the receptor for advanced glycation end products, attenuating myelopoiesis, and promoting M2 macrophage polarization in mouse models [65, 66]

Late side effects still deserve attention

Further studies should now focus on non-inferiority studies comparing these new oral molecules against currently recommended injectable GLP-1 RAs to have a clear comparison between these families of medications

Retatrutide is not just another incretin mimetic